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DEAR EDITOR, Despite psoriasis being a common disease, sur-
prisingly little guidance exists on clinical diagnostic criteria.1
The variable presentation of psoriasis and its differential diag-
noses make diagnosis challenging,2 particularly for nonderma-
tologists.
In 2016, the World Health Organization declared psoriasis
a global health concern and highlighted the need to tackle the
problem of missed or delayed diagnosis of psoriasis.3 In addi-
tion, the UK Psoriasis Association’s priority setting partnership
listed the top-10 priority research questions on psoriasis; sec-
ond on this list was ‘Does treating psoriasis early (or proac-
tively) reduce the severity of the disease, make it more likely
to go into remission, or stop other health conditions develop-
ing?’4 In order to answer this question, an accurate and timely
diagnosis of psoriasis is needed.
In response, the Global Psoriasis Atlas, a collaboration
between three leading international organizations in world
dermatology [International Federation of Psoriasis Associa-
tions; International League of Dermatological Societies; and
International Psoriasis Council (IPC)] sought to develop
clinical diagnostic criteria for chronic plaque psoriasis (CPP)
in adults.
To address this, three rounds of an e-Delphi consensus sur-
vey was undertaken from January to August 2019 to establish
diagnostic criteria. Panel members were 50 IPC councillors
recruited from 27 countries across six continents, all of whom
were consultant dermatologists.
After a literature review, 21 potential diagnostic criteria
were initially extracted. Using a 9-point Likert scale, partici-
pants were asked to rank the importance of the proposed
items,5,6 ranging from ‘extremely unimportant’ to ‘ex-
tremely important’. Consensus for inclusion was defined as
a median score of ≥ 7 (interquartile range 7–9). Consensus
for exclusion and neutral corresponded to median scores of
≤ 3 and 4–6, respectively. Participants were also asked to
nominate other diagnostic items that they incorporate into
their daily practice when diagnosing psoriasis and to com-
ment on the terminology used in the proposed list of
items.
Participants were also invited to review a proposed defini-
tion of CPP and summary of feedback from each round. Par-
ticipants were further asked to designate the items that had
received a median score of ≥ 7 as either ‘essential’ or ‘sup-
portive’ criteria, and to give their opinions about the number
of supportive criteria required to accompany the essential
criteria in the final diagnostic dataset.
Table 1 Final diagnostic dataset
Definition CPP is a systemic, inflammatory disease that predominately affect the skin. Skin lesions can occur on
any part of the body and particularly affect extensor surfaces of the limbs, especially elbows and
knees. Other common sites for psoriasis to appear include the trunk, the umbilicus, over the lower
back (sacrum), on the scalp involving the hairline, skin inside and behind the ears, the palms of the
hands, soles of the feet and nails. Skin folds such as armpits, between the buttocks, genitals and
under the breast may also be affected
Diagnosis A clinical diagnosis of CPP in adults requires the presence of the essential criterion and at least four
out of the eight supportive criteria listed below
Essential clinical diagnostic
criteriona
Well-demarcated lesion with or without silvery/white scales
Supportive clinical examination
diagnostic criteriab
Lesions are pink to red in colour. In deeply pigmented skin, lesions may be grey in colour
Lesions vary in size
Lesions are palpable
Lesions are symmetrically distributed
Family history of psoriasis in first-degree relatives
Nail involvement (e.g. pitting, onycholysis and subungual hyperkeratosis of the nails)
Joint pain and/or stiffness
Itching
CPP, chronic plaque psoriasis. aEssential criteria: those that must be present to make a clinical diagnosis of psoriasis. bSupportive criteria:
those that did not need to be present but whose presence in conjunction with other diagnostic criteria supported a diagnosis of psoriasis.
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After three rounds of the e-Delphi consensus exercise, the
final diagnostic tool consists of a definition of CPP, one essen-
tial diagnostic criterion and eight supportive diagnostic criteria
(Table 1). Thirty-two panel members agreed that at least four
of the eight supportive diagnostic criteria must be present
together with the essential criterion to make a diagnosis of CPP.
The consensus exercise included a recommendation for the
clinical diagnosis of CPP across diverse ethnic groups. The defi-
nition of CPP highlighted the most common body sites affected
by various clinical variants of psoriasis (e.g. intertriginous and
scalp psoriasis). The consensus-developed criteria are intended
to standardize psoriasis case definition for epidemiological field
studies. This is especially important in helping nondermatolo-
gist investigators identify psoriasis, particularly in resource-poor
settings, thus facilitating comparison and tracking trends of pso-
riasis incidence and prevalence in different countries. The diag-
nostic criteria could also serve as a teaching and training tool
for healthcare providers involved in psoriasis management (e.g.
nurses, pharmacists and doctors in training), especially in those
parts of the world where access to specialist dermatology care
is limited. Future research will involve implementing the con-
sensus-agreed diagnostic criteria in an online educational tool
supported by illustrations and clinical images to improve the
diagnostic abilities of nondermatologists such as general practi-
tioners and other healthcare workers.
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